SPDR S&P Biotech (XBI)

Add to Watchlists
Create an Alert
156.08 -0.51  -0.33% NYSE Arca Oct 17, 8:00PM BATS Real time Currency in USD
View Full Chart
XBI Price Chart

XBI Description

SPDR S&P Biotech is a long only equity fund managed by SPDR State Street Global Advisors that tracks the S&P Biotechnology Select Industry TR USD index and has 1.305B USD assets under management. It has an expected distribution yield of 0.99%, a Forecasted PE Ratio of 38.19, and a Forecasted Price to Book Value of 4.237. The fund has a net expense ratio of 0.35%, turns over its positions 86.00% per year, and is traded on the New York Stock Exchange Arca.

Benchmark Index: S&P Biotechnology Select Industry TR USD

XBI Key Info

Expense Ratio (6-30-14) 0.35%
Assets Under Management (10-17-14) 1.305B
30-Day Average Volume (10-17-14) 476084.0
Net Asset Value (10-17-14) 156.26
Discount or Premium to NAV (10-16-14) -0.17%
Turnover Ratio (6-30-14) 86.00%

XBI Asset Allocation

Type % Net % Long % Short
Cash 0.22% 0.22% 0.00%
Stock 99.78% 99.78% 0.00%
Bond 0.00% 0.00% 0.00%
Convertible 0.00% 0.00% 0.00%
Preferred 0.00% 0.00% 0.00%
Other 0.00% 0.00% 0.00%
As of Oct. 17, 2014

XBI Region Exposure

Americas 97.61%
North America 97.61%
Latin America 0.00%
Greater Europe 2.39%
United Kingdom 0.00%
Europe Developed 2.39%
Europe Emerging 0.00%
Africa/Middle East 0.00%
Greater Asia 0.00%
Japan 0.00%
Australasia 0.00%
Asia Developed 0.00%
Asia Emerging 0.00%
Market Classification
% Developed Markets 100.0%
% Emerging Markets 0.00%
As of Oct. 17, 2014
Region breakdown data is calculated by using the long position holdings of the portfolio.

XBI Stock Sector Exposure

Basic Materials 0.00%
Communication Services 0.00%
Consumer Cyclical 0.00%
Consumer Defensive 0.00%
Energy 0.00%
Financial Services 0.00%
Healthcare 100.0%
Industrials 0.00%
Real Estate 0.00%
Technology 0.00%
Utilities 0.00%
As of Oct. 16, 2014

XBI Stock Market Capitalization

Giant 4.90%
Large 4.01%
Medium 14.85%
Small 27.78%
Micro 48.24%
As of Oct. 16, 2014
View More Holdings

XBI Top 10 Holdings

Name % Weight Price Chg %
Agios Pharmaceuticals Inc 1.90% 64.27 -1.02%
Chimerix Inc 1.58% 34.15 -3.53%
Repligen Corp 1.58% 22.50 +0.99%
AMAG Pharmaceuticals Inc 1.57% 30.65 +0.00%
Alnylam Pharmaceuticals Inc 1.55% 86.18 +1.46%
Merrimack Pharmaceuticals Inc 1.52% 8.44 -2.88%
Inovio Pharmaceuticals Inc 1.51% 12.31 +3.97%
PTC Therapeutics Inc 1.48% 37.03 -1.38%
Exact Sciences Corp 1.48% 23.77 +1.06%
Vertex Pharmaceuticals Inc 1.44% 102.35 +1.08%
As of Oct. 17, 2014
Get Quote for
Advertisement

XBI Risk Info

Beta 1.160
30 Day Average Volatility 30.91%

XBI Fundamentals

Dividend Yield TTM (10-17-14) 0.99%
Weighted Average PE Ratio --
Weighted Average Price to Sales Ratio 12.85
Weighted Average Price to Book Ratio 6.060
Weighted Median ROE -20.02%
Weighted Median ROA -22.84%
Forecasted Dividend Yield 0.03%
Forecasted PE Ratio 38.19
Forecasted Price to Sales Ratio 9.734
Forecasted Price to Book Ratio 4.237
Number of Holdings 83.00
As of Oct. 17, 2014

XBI Growth Estimates

Forecasted 5 Yr Earnings Growth 19.41%
Forecasted Book Value Growth 8.17%
Forecasted Cash Flow Growth 23.89%
Forecasted Earnings Growth 22.52%
Forecasted Revenue Growth -2.85%
As of Oct. 17, 2014

XBI Performance

  Returns Total Returns
1M -2.32% -1.98%
3M 15.94% 16.35%
6M 24.48% 25.42%
1Y 24.60% 25.85%
3Y 150.6% 154.1%
5Y 201.0% 205.2%
As of Oct. 17, 2014

XBI Flows

1M 16.88M
3M 77.30M
6M -165.35M
YTD 64.51M
1Y 129064.9
3Y 159.80M
5Y 103.47M
As of Sept. 30, 2014
Advertisement

You've hit the 10 page limit on YCharts.

Experience the power of YCharts Professional.
Start your Free 14-Day Trial.

Start My Free Trial No credit card required.

Already a subscriber? Sign in.

{{root.upsell.info.feature_headline}}.

{{root.upsell.info.feature_description}}
Start your free 14 Day Trial.

{{root.upsell.info.button_text}} No credit card required.

Already a subscriber? Sign in.